hh

Hh-Ag1.5 (SAG-1.5) is a potent Hedgehog (Hh) agonist (EC50: 1 nM) and Smoothened (Smo) receptor agonist, with an EC50 of 1 nM and Ki values between 0.5 and 2.3 nM for Smo. Hh-Ag1.5-mediated reprogramming breaks the quiescent state of non-injured hepatic stem cells and thus rescues liver failure. Hh-Ag1.5 induced differentiation of hiPSCs into skin precursor cells, spinal motor neurons and spinal sensory neurons.

HH-2853 is a potent inhibitor targeting EZH1/2, demonstrating significant antitumor activity. Its IC50 values for both wild-type and mutant EZH2 range from 2.21-5.36 nM, comparable to tazemetostat. HH-2853 is more effective against EZH1, with an IC50 of 9.26 nM, notably lower than tazemetostat's 58.43 nM. However, at concentrations up to 10 μM, it exhibits minimal inhibitory activity on 36 types of histone-modifying enzymes. On the cellular level, HH-2853 effectively inhibits mono-, di-, and tri-methylation of H3K27 in various cancer cell lines with wild-type or mutant EZH2, without affecting other methylation types on histone H3 at concentrations up to 10 μM. Additionally, HH-2853 significantly reduces cell viability in multiple cancer cell lines carrying EZH2 GOF mutations or SWI/SNF complex alterations, and demonstrates superior antitumor effects compared to tazemetostat in several tumor xenograft models at equivalent doses.

CDK9 inhibitor HH1 (8019-9719) is an inhibitor of the human CDK2-cyclin A2 complex with an IC50 value of 2 μM.

(S)-HH2853 is a potent dual inhibitor of EZH1 and EZH2, inhibiting EZH2_Y641F with an IC50 of <100 nM.(S)-HH2853 has potential antitumor activity and can be used in the study of autoimmune diseases.

(R)-HH2853 is a potent EZH2 inhibitor with an IC50 <100 nM for EZH2-Y641F.(R)-HH2853 has anticancer and antitumor activity and can be used in autoimmune diseases.

HH-Folic acid derives from vitamin B9.

HH0043 (Compound 10f) is an orally active and potent inhibitor of SOS1, exhibiting an IC50 of 5.8 nM. It is applicable in cancer research.

IDR-HH2 is an immunoregulatory peptide with the ability to modulate the host cytokine/chemokine environment. It enhances the adhesion of monocytes and THP-1 cells to fibronectin. Additionally, IDR-HH2 exhibits antibacterial activity, inhibiting P. aeruginosa and S. aureus with MIC values of 75 µg/mL and 38 µg/mL, respectively.

HHQ (2-heptylquinolin-4(1H)-one) is a PqsR antagonist.

HHS-0701 is a sulfur-triazole exchange (SuTEx) ligand. HHS-0701 is a potent inhibitor of tyrosine-reactive prostaglandin reductase 2 (PTGR2). HHS-0701 can block PTGR2 metabolism of the lipid substrate 15-Keto-PGE2.

CysHHC10 acetate shows antibacterial activities against both Gram-positive and Gram-negative bacteria with MIC of 10.1, 20.2, 2.5, and 1.3 mM for E. coli, P. aeruginosa, S. aureus, and S. epidermidis, respectively.

HhAntag is a small molecule inhibitor of GLI1-mediated transcription, an essential down-stream element of the Hedgehog (Hh) pathway with the anti-tumor activity.

HHP 9 is an effective BET bromodomain degrader (PROTAC).

p-F-HHSiD (p-Fluorohexahydrosiladifenidol) hydrochloride is a selective M3mAChR antagonist. It is capable of inhibiting acetylcholine-mediated vasodilation in human umbilical vein endothelial cells (HUVEC).

HHL-6 is a c-Fos and BDNF protein expression modulator.

12(S)-HHT (12(S)-HHTrE), a fatty acid produced via the arachidonic acid metabolic pathway of cyclooxygenase (COX), is an endogenous ligand and agonist of BLT2, and the 12(S)-HHT/BLT2 axis plays a role in the maintenance of homeostatic aspects of epithelial tissues and in inflammatory responses. 12(S)-HHT inhibits the p38 MAPK/NF-κB pathway through upregulation of MKP-1, leading to reduced IL-6 synthesis in UVB-irradiated HaCaT cells.

Yhhu-3792 activates Notch signaling pathway and promotes the expression of Hes3 and Hes5. Yhhu-3792 enhanced the self-renewal ability of neural stem cells (NSCs), expanded the NSC pool and promoted endogenous neurogenesis in the dentate gyrus (DG) of the hippocampus in mice. Yhhu-3792 can improve the situational and spatial memory ability of mice. Yhhu-3792 has research potential in DG dysfunction related to memory impairment.

Galloyl-bis-HHDP glucose (HeT), an ellagitannin, exhibits phytoprotective effects against Pseudomonas viridiflava [1].

HHV-2 Envelope Glycoprotein G (552-574), an immunodominant region within glycoprotein G (gG-2), demonstrates reactivity with all herpes simplex (HSV-2) sera [1].

FITC-εAhx-HHV-2 Envelope Glycoprotein G (561-578) is a fluorescein isothiocyanate (FITC)-labeled segment of the HHV-2 Envelope Glycoprotein G encompassing amino acids 561 to 578. This immunodominant region of glycoprotein G (gG-2) exhibits reactivity with all herpes simplex virus type 2 (HSV-2) sera [1].

The compound AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG facilitates bone ossification and has potential applications in the study of conditions associated with osteogenic insufficiency or diminished bone mineral density (BMD), including osteoporosis [1].

Yhhu-3792 hydrochloride is a compound that bolsters the self-renewal capacity of neural stem cells (NSCs), catalyzes the Notch signaling pathway, and upregulates expression of Hes3 and Hes5. It augments the NSC pool, stimulates endogenous neurogenesis in the mouse hippocampal dentate gyrus (DG), and enhances mice's spatial and episodic memory skills. This compound shows promise for researching learning and memory impairments linked to DG dysfunction [1].

Pinocembrin 7-O-[4",6"-(S)-HHDP]-β-D-glucoside, is a complex polyphenol compound that has been shown to exhibit modest antiproliferative effects in platelet-derived growth factor (PDGF)-induced HSC-T6 hepatic stellate cells with an IC50 of 200 μM. further experiments confirm that Pinocembrin 7-O-[4",6"-(S)-HHDP]-β-D-glucoside possesses a more remarkable anti-proliferative effect specifically against activated hepatic stellate cells (HSCs), which are key drivers of liver fibrosis.

CysHHC10 is a synthetic antimicrobial peptide (AMP) that exhibits strong antimicrobial properties against both Gram-positive and Gram-negative bacteria.